10-Q: Corvus Pharma Q3 2025: Clinical Progress Amidst Funding Needs

Corvus Pharmaceuticals reports reduced net loss in Q3 2025 driven by warrant revaluation, positive clinical data for soquelitinib, but faces substantial doubt about its ability to continue as a going concern.

Summary

• Reported a net loss of $10.2 million for the three months ended September 30, 2025, a significant reduction from $40.2 million in the same period last year, primarily due to a non-operating gain from the change in fair value of warrant liability.
• For the nine months ended September 30, 2025, net loss was $3.0 million, down from $50.2 million in the prior year, also largely influenced by the warrant liability revaluation.
• Research and development expenses increased to $8.5 million for the three months and $23.8 million for the nine months ended September 30, 2025, reflecting increased investment in soquelitinib programs.
• Cash, cash equivalents, and marketable securities totaled $65.7 million as of September 30, 2025.
• The company has initiated a registrational Phase 3 clinical trial for soquelitinib in relapsed/refractory peripheral T cell lymphoma (PTCL) in late 2024.
• Interim data from the Phase 1/1b trial of soquelitinib in T cell lymphomas showed an objective response rate (ORR) of 39% (9 of 23 evaluable patients) with 6 complete responses (CRs) and 3 partial responses (PRs), and a median duration of response of 17.2 months.
• Interim data from the Phase 1 clinical trial of soquelitinib in atopic dermatitis showed a mean Eczema Area and Severity Index (EASI) reduction of 64.8% in the 200 mg BID cohort at Day 28, compared to 34.4% for placebo.
• Data for ciforadenant in metastatic renal cell carcinoma (RCC) showed an overall response rate (ORR) of 44%, but the deep response rate of 34% was not statistically significant compared to historical controls.
• All common warrants from the May 2024 registered direct offering have been exercised, generating $54.3 million in proceeds during the nine months ended September 30, 2025.
• The company has an at-the-market (ATM) offering program with Jefferies LLC, with $100.0 million remaining available for sale as of September 30, 2025.
• Management concluded that substantial doubt exists about the company's ability to continue as a going concern for at least 12 months from the date of the financial statements' issuance, requiring additional capital by Q4 2026.

Sentiment

Score: 4

Explanation: While soquelitinib shows promising clinical progress and has received Fast Track and Orphan Drug designations, the company's explicit "going concern" warning and increased cash burn are significant financial negatives. The ciforadenant trial results were not statistically significant, adding to the mixed outlook. The need for substantial additional capital by Q4 2026 highlights financial instability.

Positives

• Significant reduction in net loss for both the three and nine months ended September 30, 2025, primarily due to a non-operating gain from warrant liability revaluation.
• Positive interim clinical data for soquelitinib in relapsed/refractory T cell lymphomas, showing an objective response rate of 39% (6 CRs, 3 PRs) and a median duration of response of 17.2 months.
• The 18-month progression-free survival (PFS) rate of 30% for soquelitinib in T cell lymphomas compares favorably to <20% with existing standard of care treatments like belinostat or pralatrexate.
• Soquelitinib received Fast Track designation from the FDA for relapsed or refractory PTCL and Orphan Drug Designation for T cell lymphoma.
• Promising interim results from the Phase 1 clinical trial of soquelitinib in atopic dermatitis, with the 200 mg BID cohort achieving a 64.8% mean EASI reduction at Day 28, significantly better than placebo's 34.4%.
• 50% of patients in the 200 mg BID cohort for atopic dermatitis achieved IGA 0 or 1 or EASI 75 at Day 28, which are clinically meaningful endpoints.
• Soquelitinib was well tolerated across all clinical trials, with no dose-limiting toxicities or clinically significant laboratory abnormalities reported in over 100 patients treated.
• Successful exercise of all common warrants from the May 2024 offering generated $54.3 million in proceeds, strengthening the capital base.
• Increased interest income due to higher cash equivalents and marketable securities.

Negatives

• The company continues to incur significant operating losses, with an accumulated deficit of $400.0 million as of September 30, 2025.
• Cash and cash equivalents decreased to $2.9 million as of September 30, 2025, from $8.7 million at December 31, 2024.
• Net cash used in operating activities increased to $23.6 million for the nine months ended September 30, 2025, from $17.0 million in the prior year, indicating increased cash burn.
• Substantial doubt exists about the company's ability to continue as a going concern for at least 12 months from the date of the financial statements' issuance, requiring additional funding by Q4 2026.
• Research and development expenses significantly increased, reflecting higher costs for clinical trials and drug manufacturing.
• Clinical data for ciforadenant in metastatic RCC showed a deep response rate of 34%, which was not statistically significant compared to the historical control of 32% for ipilimumab and nivolumab alone.
• Development of mupadolimab is being delayed to prioritize other product candidates, indicating a potential slowdown or reprioritization of that program.
• The company has not generated any revenue from product sales to date and expects operating losses to continue for the foreseeable future.

Risks

• Incurred significant operating losses since inception and expects to incur significant losses for the foreseeable future, with no guarantee of profitability.
• Requires substantial additional financing to achieve goals; failure to obtain capital could force delays, reductions, or termination of product development or commercialization efforts.
• Product candidates are in various stages of development and may fail or suffer delays, materially and adversely affecting commercial viability.
• Clinical drug development is a lengthy, expensive process with an uncertain outcome, and early clinical trial results are not necessarily predictive of future results.
• Termination, suspension, or delays in planned clinical trials could increase costs, delay revenue generation, and adversely affect commercial prospects.
• Product candidates are subject to extensive, costly, and time-consuming regulation, which may cause unanticipated delays or prevent required approvals.
• FDA may not accept data from clinical trials conducted in foreign locations, potentially requiring additional costly and time-consuming trials.
• Difficulties enrolling subjects in clinical trials could delay or adversely affect clinical development activities.
• Occurrence of serious complications or side effects in clinical trials or post-approval could lead to discontinuation of programs, refusal of regulatory approval, or revocation of marketing authorizations.
• Fast Track designation does not guarantee faster development, review, or approval, nor does it increase the likelihood of regulatory approval.
• Failure to identify additional product candidates.
• Reliance on third parties to conduct clinical trials, manufacturing, research, and preclinical testing, who may not perform satisfactorily or meet deadlines.
• Inability to successfully scale-up manufacturing of product candidates in sufficient quality and quantity could delay or prevent development and commercialization.
• Reliance on third parties requires sharing trade secrets, increasing the risk of discovery by competitors or misappropriation.
• Inability to commercialize product candidates or significant delays in obtaining regulatory approval would materially and adversely affect the business.
• Failure to achieve projected development goals in expected time frames could delay commercialization and cause stock price decline.
• Competition from entities developing novel treatments and technology platforms could adversely affect the ability to develop and commercialize product candidates.
• Approved products could be subject to restrictions or withdrawal from the market, and the company may face penalties for non-compliance.
• Failure to obtain or maintain adequate coverage and reimbursement for approved products could limit marketing ability and decrease revenue.
• Governments may impose price controls, adversely affecting future profitability.
• Operating results may fluctuate significantly, making future results difficult to predict.
• Dependence on key personnel, particularly President and CEO Richard A. Miller, M.D., and other key executives.
• Difficulties in managing growth and expanding operations successfully.
• Subject to various federal and state healthcare laws and regulations; failure to comply could harm results of operations and financial condition.
• Use of biological and hazardous materials carries risks of claims relating to improper handling, storage, or disposal.
• Inherent risk of product liability lawsuits from clinical testing and commercialization.
• Obligation to report adverse medical events; failure to do so would result in sanctions.
• Employees, contractors, and vendors may engage in misconduct or improper activities.
• Intellectual property rights are subject to terms of licenses, challenges, and potential infringement by third parties.
• Changes in U.S. patent law could diminish the value of patents.
• Inability to protect intellectual property rights throughout the world.
• Intellectual property rights may not address all potential threats to competitive advantage.
• Information technology systems may fail or suffer security breaches, disrupting product development.
• Changes in and failures to comply with U.S. and foreign privacy and data protection laws.
• Operations could be subject to earthquakes, power shortages, and other natural or manmade disasters.
• Reliance on single suppliers for drug substance could lead to disruptions.
• Ability to use net operating loss carryforwards and other tax attributes may be limited by ownership changes.
• Negative research or reports from securities analysts could cause stock price and trading volume to decline.
• Failure to adhere to Nasdaq listing requirements could lead to delisting.
• Principal stockholders and management own a significant percentage of stock, exerting significant control.
• No current intention to pay dividends; return on investment depends on stock appreciation.
• Sales of substantial number of shares by existing stockholders could cause stock price to fall.
• Smaller reporting company status may make common stock less attractive to investors.
• Failure to maintain proper and effective internal control over financial reporting could impair financial statements.
• Provisions in charter documents and Delaware law could discourage takeovers.
• Exclusive forum provision limits stockholders' ability to choose judicial forum.
• Future growth depends on operating in foreign markets, subject to additional regulatory burdens.
• Changes to applicable U.S. or foreign tax laws and regulations may have an adverse effect.
• Disruptions at the FDA and other government agencies caused by funding shortages, staff reductions or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all.

Future Outlook

The company expects operating losses to continue for the foreseeable future as it advances soquelitinib, ciforadenant, and mupadolimab through clinical development, seeks regulatory approval, and prepares for commercialization. Substantial additional funding will be required by the fourth quarter of 2026 to support continuing operations, which the company intends to raise through equity offerings, debt financings, and potential collaborations. Final data from the Phase 1/1b T-cell lymphoma clinical trial is expected in December 2025, and data from the soquelitinib atopic dermatitis extension cohort 4 is anticipated in January 2026. A Phase 2 clinical trial in atopic dermatitis is planned to open for enrollment in early Q1 2026. The company also continues to advance next-generation ITK inhibitor preclinical product candidates.

Management Comments

• "We believe our proprietary product candidates have broad potential to address cancers, immune mediated diseases and inflammatory diseases."
• "We believe this strategy has enabled us to move rapidly from preclinical to clinical trials in diverse disease areas, each with large unmet needs."
• "We believe highly selective inhibitors of this enzyme will facilitate induction of normal T cell anti-tumor immunity and may be useful in the treatment of solid tumors as well as lymphomas."
• "We believe, based on our preclinical and Phase 1/1b data from our T cell lymphoma clinical trial, that soquelitinib has the potential to reprogram normal immune responses that also could be beneficial for the treatment of certain autoimmune, inflammatory and allergic diseases."
• "We are considering evaluating soquelitinib in clinical trials of solid tumors in the future."
• "We expect our losses will increase as we continue our development of, seek regulatory approval for and begin to commercialize, soquelitinib, ciforadenant and mupadolimab, and as we develop other product candidates."
• "Management has concluded that substantial doubt exists about our ability to continue as a going concern for at least 12 months from the date of the issuance of these condensed consolidated financial statements."

Industry Context

The biopharmaceutical industry is characterized by high R&D costs, lengthy development timelines, and significant regulatory hurdles. Corvus Pharmaceuticals operates in the competitive oncology and immunology therapeutics fields, where there is intense and rapidly evolving competition from larger, better-funded companies and academic institutions. The focus on ITK inhibition for T-cell lymphomas and atopic dermatitis, and A2A receptor antagonism for RCC, positions the company within active areas of drug development. The company's strategy to leverage T-cell modulation for diverse disease areas aligns with broader industry trends seeking targeted immune therapies. The challenges in securing additional funding and the "going concern" warning are common for early-stage biopharmaceutical companies that have not yet commercialized products. The impact of healthcare reform measures and potential price controls also reflects ongoing industry-wide pressures.

Comparison to Industry Standards

• Soquelitinib's 18-month progression-free survival (PFS) rate of 30% in T-cell lymphomas compares favorably to <20% with existing standard of care treatments like belinostat or pralatrexate.
• The deep response rate of 34% for ciforadenant in combination therapy for metastatic RCC was not statistically significant compared to the historical control of 32% for ipilimumab and nivolumab alone, suggesting it did not significantly outperform established combination therapies in this specific metric.
• The EASI 75 and IGA 0 or 1 endpoints achieved by soquelitinib in atopic dermatitis are recognized by the FDA as clinically meaningful and approvable endpoints, aligning with standards used for other FDA-approved treatments for atopic dermatitis.

Legal Proceedings

• Not currently a party to any material litigation or legal proceedings.

Related Party Transactions

• In the May 6, 2024 registered direct offering, related parties including OrbiMed Advisors LLC (Peter Thompson, Director), Puissance Capital Management (Ted Wang, Director of Angel Pharmaceuticals), Richard A. Miller, M.D. (President, CEO, Chairman), and William B. Jones, Ph.D. (SVP, Pharmaceutical Development) purchased common stock, pre-funded warrants, and common warrants.
• During the three months ended June 30, 2025, common warrants sold to these related parties were exercised, generating proceeds of $2,935,135 from Puissance Capital Management, $1,956,756 from Richard A. Miller, M.D., and $67,750 from William B. Jones, Ph.D.
• OrbiMed Advisors LLC exercised 1,397,684 common warrants on a cashless basis, resulting in the issuance of 221,352 shares.
• The company recorded approximately $117,000 in clinical trial expenses with ICON plc during the three months ended September 30, 2025, where Linda S. Grais, M.D., J.D., a member of the company's Board of Directors, is a non-executive board member.

Stakeholder Impact

• Shareholders face potential for significant dilution from future capital raises and stock price volatility due to clinical trial results, regulatory approvals, and the company's financial condition. There is a risk of substantial losses if the company cannot secure funding or commercialize products.
• Employees' continued employment and potential for stock-based compensation are tied to the company's ability to secure funding and advance product candidates, with a risk of workforce reductions if funding is not secured.
• Future customers may gain access to new treatments for T-cell lymphomas and atopic dermatitis if soquelitinib is approved, but there is uncertainty regarding ciforadenant's market impact given its non-statistically significant results.
• Suppliers and Contract Research Organizations (CROs) depend on the company's financial health and ability to secure ongoing funding for R&D and manufacturing for their continued engagement and payment for services.
• Creditors face risk associated with the company's "going concern" status and its stated need for additional financing.

Next Steps

• Present final data from the Phase 1/1b T-cell lymphoma clinical trial at the Annual ASH meeting in December 2025.
• Announce data from the soquelitinib atopic dermatitis extension cohort 4 in January 2026.
• Open enrollment for a Phase 2 clinical trial in atopic dermatitis in early Q1 2026.
• Continue clinical development of soquelitinib, ciforadenant, and mupadolimab.
• Seek regulatory approval for product candidates.
• Prepare for commercialization of approved product candidates.
• Advance next-generation ITK inhibitor preclinical product candidates.
• Raise additional capital through equity offerings, debt financings, and collaborations by Q4 2026.

Key Dates

Recommendation

Despite some promising clinical data for soquelitinib, the explicit "going concern" warning, significant cash burn, and the need for substantial additional capital by Q4 2026 present a high level of financial risk. The non-statistically significant results for ciforadenant further dampen the near-term commercial prospects for that candidate. While the company has an ATM facility, its ability to raise sufficient funds on acceptable terms is uncertain, and failure to do so would severely impact operations and shareholder value. The current financial instability outweighs the clinical progress, making the stock a high-risk investment with significant downside potential.

Keywords

Biopharmaceutical, Clinical-stage, Oncology, Immunology, T cell lymphoma, Atopic dermatitis, Soquelitinib, ITK inhibitor, Ciforadenant, Adenosine A2A receptor antagonist, Mupadolimab, Anti-CD73 antibody, SEC filing, 10-Q, Financial results, Clinical trials, Drug development, Going concern, Capital raise, Biotechnology, Peripheral T cell lymphoma, Metastatic renal cell carcinoma, Orphan Drug Designation, Fast Track Designation, Nasdaq